3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Lung Neoplasms
1
Interventions
Specimen Handling
276
pembrolizumab
227
Magnetic Resonance Spectroscopy
226
Carboplatin
180
Cisplatin
166
Biopsy
166
Nivolumab
158
Cyclophosphamide
144
Radiotherapy
125
Paclitaxel
124
Gemcitabine
116
Bevacizumab
95
durvalumab
92
Dexamethasone
88
Rituximab
81
Oxaliplatin
80
venetoclax
75
atezolizumab
71
Fluorouracil
70
Docetaxel
70
Capecitabine
70
Doxorubicin
68
Etoposide
65
Radiosurgery
64
Ipilimumab
63
Radiation
61
Prednisone
60
Cytarabine
60
Lenalidomide
58
Pemetrexed
55
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Histamine H2 Antagonists
×
90 days
×
Clear all
NCT06788912
2026-06-01
MK-3475-01E
Merck Sharp & Dohme LLC
Phase 2
Recruiting
60 enrolled